Valneva H1 2026: Net Loss Triples to €63.3M on IXCHIQ Charges; Guidance Reaffirmed
VALN is trading near its 52-week low of $4.75 (15% above the low) on light trading volume (0.2× avg).
Summary
Valneva reported a first-half 2026 net loss of €63.3 million, triple the prior-year loss, due to lower sales and IXCHIQ-related charges. Full-year guidance was reaffirmed, and the filing details the April offering and Pharmakon loan terms.
Key Events · Earnings and Guidance · VALN
-
Net Loss Triples to €63.3M
First-half 2026 net loss was €63.3 million, up from €20.8 million in H1 2025, driven by lower product sales and one-time IXCHIQ charges.
-
IXCHIQ Charges Hit Gross Margin
IXCHIQ gross margin was negative, impacted by €9.7 million in external manufacturing cancellation fees and a €4.5 million non-cash inventory impairment.
-
Full-Year Guidance Reaffirmed
Product sales guidance of €135–150 million and total revenues of €145–160 million were reaffirmed despite the H1 loss.
-
April Offering Terms Detailed
The €84 million reserved offering included 15,893,817 shares with warrants at an exercise price of €2.96 per share, potentially raising an additional €47 million.
Analysis · VALN · Life Sciences
Valneva's first-half 2026 results show a net loss of €63.3 million, up from €20.8 million a year earlier, driven by lower product sales and one-time IXCHIQ-related charges including €9.7 million in manufacturing contract cancellation fees and a €4.5 million inventory impairment. The company reaffirmed full-year product sales guidance of €135–150 million and highlighted a solid cash position of €121.5 million, supported by the April reserved offering. The detailed financial statements also reveal the terms of the €84 million offering completed in April, including warrants with an exercise price of €2.96 per share, and the Pharmakon loan carrying $205.2 million at a 9.00% interest rate with no financial covenants. These specifics provide investors with a clearer picture of the company's financial health and capital structure than the earlier news summary.
At the time of this filing, VALN was trading at $5.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $537.6M. The 52-week trading range was $4.75 to $12.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.